Rewriting the book on chemo-resistant cancers with a DNA library

Related posts:

1. Five perspectives on HIV prevention pill awaiting Australian approval Australia's ambitious goal of no new cases of HIV by 2020 will be a tough deadline to meet given rates have been steadily increasing since 2000. Here, the ABC hears five perspectives on a major breakthrough in the fight against the epidemic — the preventative drug known as PrEP. ...
2. Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial. ...
3. Pembrolizumab shows real promise against head and neck cancer, study suggests Immunotherapy with the anti-PD-1 antibody pembrolizumab decreased the size of tumors by 30 percent or more in 24.8 percent of 132 patients with recurrent or metastatic head and neck cancer. That's nearly twice as effective as the current preferred treatment. ...
4. Targeted drug can ‘diminish the suffering’ of myelofibrosis Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. ...
5. Altered pain processing in patients with cognitive impairment People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a new research review. ...